

# Preference Value Mapping for Acute Lymphoblastic Leukaemia (ALL) treatments

Exploring treatment preferences of people living with ALL

## Aim

To investigate the importance of treatment attributes, and the trade-offs associated with treatment options, that people living with ALL are willing to make.

## Who we asked...

We conducted an online survey with 49 participants (36 adults with ALL, 13 caregivers of children with ALL).

People indicated their preferences for treatments in a series of treatment scenarios. They were also asked about diagnosis, burden and impact of ALL.

## What we did...

We asked participants to trade off the importance of the following attributes of treatments for ALL, to determine what was most important to them



## What we found...

### Impact of ALL

#### High physical impact:



- 64% of adults and 77% of children were impacted physically - experiencing side effects during treatment and/or ongoing physical limitations or impairment because of ALL

#### Mixed emotional impact:



- Over a third of participants reported an emotional impact - the majority negative
- Negative impacts included stress and anxiety
- Some participants reported re-evaluating their lives in a positive way

#### Child patients greater social impact:



- 77% of children were affected socially vs. 36% of adults
- Impacts included a lack of connection with other children, loss of education and sporting activities
- Adults suffered with extended stays away from family, due to hospitalisations

#### Low financial impact:



- Less than a third of participants (28% of adults and 24% of carers) reported a financial impact

## Treatment preferences

Based on participants' responses, we categorised people into two segments that explained their pattern of preferences (NB these groups did not differ in demographic characteristics). We also looked at B-cell participants only:

### Segment 1 - 51% of participants


The preferences of participants in this group were characterised by the importance placed on multiple treatment factors including: an overall increase in survival, hospitalisation time, a treatment with fewer severe side effects, and an extended average remission period.

### Segment 2 - 49% of participants

The preferences of participants in this group were characterised by the importance placed on overall survival followed by out of pocket cost of treatment and how the treatment is taken (oral treatments would be preferred over injectable treatments).

#### B-cell sub-group (N=40)

Again, overall survival was most important to this group, followed by out of pocket cost of treatment and hospitalisation time.



The results presented above are based on the 'Acute Lymphoblastic Leukaemia Patient Value Mapping Study' conducted by CaPPRe for Amgen Australia. Data was collected in 2017/18. Our thanks to the Leukaemia Foundation for their support in recruitment.

Patients should consult their Health Care Professional about which treatment choices are best for them.